Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Ascentage Pharma Group International (AAPG)

$17.25 -0.14 (-0.81%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	315,441
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A

Company Profile

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MD...

Industry: Biotechnology

Sector: Healthcare

Phone: 86 512 8555 7777

Website: www.ascentage.cn

Address:

Suzhou Industrial Park, 68 Xinqing Road, Suzhou, China

k3vl4r Aug. 23 at 7:25 PM

The big surprise? $AAPG is about to explode next week, closing the week on a 49.7% EPS estimate and heading into tomorrow’s open with a 71.7% boost. The 21.9pp jump means we’re looking at a strong catalyst for the weekend and beyond. https://app.k3vl4r.com/forecast/AAPG?utm_source=x&utm_medium=social&utm_campaign=signal&utm_content=AAPG #AAPG

0 · Reply

EarningsInsider Aug. 21 at 11:01 AM

https://www.marketbeat.com/earnings/reports/2026-8-19-ascentage-pharma-group-international-stock-1/ $AAPG Ascentage Pharma Group Internati

0 · Reply

Ascentage Pharma to Participate in Four Upcoming Investor Conferences

2026-08-20T18:00:11.000Z - 18 days ago

Half Year 2026 Ascentage Pharma Group International Earnings Presentation Transcript

Thu, 20 Aug 2026 11:05:50 -0400 - 18 days ago

Ascentage Pharma Group International H1 Earnings Call Highlights

Aug 20, 2026, 8:00 AM EDT - 18 days ago

Ascentage Pharma Group International Earnings Call Transcript: H1 2026

Aug 20, 2026, 8:00 AM EDT - 18 days ago

Ascentage Pharma Group International Earnings release: H1 2026

Aug 20, 2026, 8:00 AM EDT - 18 days ago

Ascentage Pharma Group International Slides: H1 2026

2026-08-20T07:41:42.000Z - 18 days ago

Ascentage Pharma Loss H1 Revenue Jumps 29%; Advances Olverembatinib And Lisaftoclax Programs

Wed, 19 Aug 2026 19:00:00 -0400 - 19 days ago

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

Thu, 13 Aug 2026 08:00:00 -0400 - 25 days ago

Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit

Wed, 05 Aug 2026 09:07:00 -0400 - 4 weeks ago

CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

Wed, 05 Aug 2026 08:00:00 -0400 - 4 weeks ago

Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

2026-08-03T07:58:32.000Z - 5 weeks ago

Ascentage Appoints Miyara As CBO And Ziegler As COO To Support Global Expansion

2026-08-03T00:00:14.000Z - 5 weeks ago

Ascentage Pharma appoints Miyara as CBO, Ziegler as CCO

Sun, 02 Aug 2026 19:30:00 -0400 - 5 weeks ago

Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer

Sun, 26 Jul 2026 19:30:00 -0400 - 6 weeks ago

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

2026-07-20T10:05:05.000Z - 7 weeks ago

Ascentage Pharma files to sell American Depositary Shares, no amount given

2026-06-15T11:24:34.000Z - 2 months ago

Ascentage Pharma assumed with an Outperform at Oppenheimer

2026-06-14T23:50:05.000Z - 2 months ago

Ascentage Pharma announces clinical updates from EHA2026

Sun, 14 Jun 2026 19:30:00 -0400 - 2 months ago

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

2026-06-10T12:29:42.000Z - 2 months ago

Ascentage Pharma initiated with a Buy at B. Riley

Jun 3, 2026, 8:10 AM EDT - 3 months ago

Ascentage Pharma Group International Transcript: Jefferies Global Healthcare Conference 2026

2026-06-01T00:40:50.000Z - 3 months ago

Ascentage Pharma presents data on olverembatinib

2026-06-01T00:40:06.000Z - 3 months ago

Ascentage Pharma presents data from Phase 1b study of olverembatinib

2026-06-01T00:35:05.000Z - 3 months ago

Ascentage Pharma presents first dataset of alrizomadlin

Sun, 31 May 2026 19:30:00 -0400 - 3 months ago

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

Sun, 31 May 2026 19:30:00 -0400 - 3 months ago

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

Sun, 31 May 2026 19:30:00 -0400 - 3 months ago

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

Thu, 21 May 2026 20:00:00 -0400 - 3 months ago

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

Tue, 12 May 2026 22:15:00 -0400 - 3 months ago

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

Tue, 12 May 2026 08:00:00 -0400 - 3 months ago

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

2026-04-24T09:25:32.000Z - 4 months ago

Ascentage Pharma initiated with a Buy at Deutsche Bank

Tue, 21 Apr 2026 20:00:00 -0400 - 4 months ago

Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

Sun, 19 Apr 2026 20:00:00 -0400 - 4 months ago